Jupiter Neurosciences shares are trading higher after the company announced the first patient has been dosed in its Phase 2a RESET clinical trial evaluating JOTROL in patients with Parkinson’s disease.

Benzinga Newsdesk www.benzinga.com Positive 94.7%

Neg 0% Neu 0% Pos 94.7%

Comments

No comments yet. Be the first!